By the end of this session, attendees will be able to:
- List two (2) major strategies employed for delivering a robust personalized medicine supply chain
- Identify at least two (2) concerns in the handling of cell and gene therapy clinical materials
- Describe potential labeling solutions appropriate to the labeling of cell and gene therapy products for transport
- Create better outcomes for patients via the creation of a robust supply chain